



		478
1	IN THE UNITED STATES DISTRI	
2	NORTHERN DISTRICT OF ILL EASTERN DIVISION	
3 4	WENDY B. DOLIN, Individually and as Independent Executor of the Estate of STEWART DOLIN, deceased,	
5	Plaintiffs,	
6	VS.) No. 12 CV 6403
7 8	SMITHKLINE BEECHAM CORPORATION, d/b/a GLAXOSMITHKLINE, a Pennsylvania Corporation,) Chicago, Illinois)
9	Defendant.) March 16, 2017) 1:30 p.m.
10	VOLUME 3-B	
11	TRANSCRIPT OF PROCEEDI	NGS
12	BEFORE THE HONORABLE WILLIAM T. HA	ART, and a Jury
13	APPEARANCES:	
14		ARISTEI & GOLDMAN, P.C. RENT WISNER
15	12100 Wilshire	AEL L. BAUM Boulevard, Suite 950
16	Los Angeles, ((310) 207-3233	California 90025
17	RAPOPORT LAW (
18	MR. MATTH	D E. RAPOPORT HEW S. SIMS
19 20	Chicago, Illir (312) 327-9880	
20		,
22	Court reporters: JUDITH A. WALS	SH, CSR, RDR, F/CRR
23	GAYLE A. McGUI	GAN, CSR, RMR, CRR born Street, Room 2504
24	Chicago, Illir (312) 435-5895	nois 60604
25	judith_walsh@i	ilnd.uscourts.gov


		479
1	APPEARANCES (continued:)	
2	For Defendant GlaxoSmithKline:	KING & SPALDING BY: MR. TODD P. DAVIS
3		MR. ANDREW T. BAYMAN 1180 Peachtree Street N.E.
4		Atlanta, Georgia 30309 (404) 572-4600
5		KING & SPALDING, LLP BY: MS. URSULA M. HENNINGER
6 7		100 North Tryon Street, Suite 3900 Charlotte, North Carolina 28202 (704) 503-2631
8		SNR DENTON US, LLP
9 10		BY: MR. ALAN S. GILBERT 233 South Wacker Drive, Suite 7800 Chicago, Illinois 60606
10		(312) 876-8000
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		











1	Q. All right. Doctor, we were just talking about Table, it
2	looks like it's 21.7 in this report that had these run-in
3	suicides. Let's go to the suicide attempts which I have
4	actually right here. So what is this, Doctor?
5	A. That's a table. Again, this would be a fairly standard
6	table certainly for antidepressant trials which includes
7	attempted suicides and overdoses. "Worldwide data" means
8	trials that happened in both the United States and outside the
9	United States.
10	Q. All right. And we have here that there were how many
11	attempts on paroxetine?
12	MR. BAYMAN: Your Honor, once again, can I ask that
13	he show the whole thing with the asterisk?
14	MR. WISNER: Your Honor, we'll get there.
15	THE COURT: All right.
16	MR. WISNER: I'm not hiding it.
17	BY MR. WISNER:
18	Q. Doctor?
19	A. Well, just all we need really to focus on is the group of
20	columns, the worldwide columns over on the right because they
21	include both U.S. and non-U.S. data.
22	Q. Is it appropriate in analyzing a risk to exclude data from
23	non-U.S. sites?
24	A. No. Arguably, you would include all. There may be
25	reasons to exclude some, but for the most part, unless there's

	Healy - direct by Wisner 486
1	a good case made, you would include all.
2	Q. And it says here that there are how many paroxetine
3	suicide attempts?
4	A. 42 here.
5	Q. And how many does it say there were for placebo?
6	A. It says there were 3.
7	Q. Now, we actually have a number under N. What is that,
8	Doctor?
9	A. That's showing that there's 554 people who were entered
10	into the placebo arm of trials.
11	Q. Now, those three people right there where it says
12	"suicides"
13	A. Yes.
14	Q were those three people in that N of 554?
15	A. Well, they weren't. As it turns out, someone like me
16	reading the document in the first instance would assume that
17	they were but as it turns out, in fact, no, they weren't.
18	Q. All right. And you see there's an asterisk on there.
19	Let's call out the asterisk here. And it says what does it
20	say, Doctor?
21	A. It says two overdoses occurred during the placebo run-in
22	period.
23	Q. So that 3 right there should be what?
24	A. It should be 1.
25	Q. And so 1 versus 42, what does that tell you?

	Healy - direct by Wisner
	487
1	A. Well, you have to take into account that there's more
2	patients go on Paxil than on placebo. This is a very big
3	difference.
4	Q. In your opinion, does it suggest that there's an
5	association between Paxil and suicide attempts?
6	A. If we're using the 1, then it does. If we're using 3,
7	then it's less clear.
8	Q. Okay. And then it says here, can you read that to the
9	jury?
10	A. "The rates for attempted suicide and drug overdose, the
11	most common subpopulation of attempted suicides, are not
12	dissimilar when Paxil is compared to other antidepressants.
13	The data in this table is not adjusted for dose exposure."
14	Q. Is that sentence accurate?
15	A. Well, as the data stands, if you assume that the three
16	figures are generally from the placebo arm of the trial,
17	it's even then it's not quite accurate in that the figures
18	for Paxil are higher, but it's definitely not accurate if the
19	figures should be 1.
20	Q. Well, should the figure be 1, Doctor?
21	A. The figure should be 1.
22	Q. So is that sentence accurate under any circumstances
23	factually?
24	A. The figure this isn't the claim that should have been
25	made about this data, in my opinion.

	Healy - direct by Wisner 488
1	Q. Is this a misrepresentation of what the data shows?
2	A. I wouldn't have represented the data this way.
3	Q. Okay. All right. Let's so this was submitted in 1989.
4	Did anything happen in the area of SSRIs and suicide after
5	1989 to bring any attention to the issue of SSRI-induced
6	suicide?
7	A. Yes. There was concerns about the issue became much
8	more of a public issue in the context of Prozac. There were
9	reports you've seen the Rothschild and Locke paper. There
10	was a paper by Martin Teicher which talked about six cases,
11	and that was focused principally on Prozac because at this
12	stage, at that stage, Prozac was on the U.S. market. It had
13	been on it a year before the UK. Paxil wasn't on the U.S.
14	market.
15	Q. All right. Turn to Exhibit 14 in your binder there,
16	Plaintiff's Exhibit 14.
17	A. Yes. I think I've got it.
18	Q. What is this document, Doctor?
19	A. This is the article by Martin Teicher that for a lot of
20	people kicked the issue off I mean, the issue about can
21	SSRI drugs, can a drug like Prozac make people suicidal.
22	Q. Okay. Great. Is this a fair and accurate copy of that?
23	A. It appears to be.
24	MR. WISNER: Your Honor, at this time, this document
25	has already been admitted into evidence. Permission to

	Healy - direct by Wisner 489
1	publish it to the jury.
2	THE COURT: All right. You may proceed.
3	BY MR. WISNER:
4	Q. Who is Dr. Teicher?
5	A. Dr. Teicher was a doctor that was working in Boston at the
6	time. I think he was associated with McLean Hospital at that
7	time.
8	Q. And who are these other people on the
9	A. Carol Glod was one of the senior nursing staff. Jonathan
10	Cole was one of the senior figures in the field. In terms
11	we've I outlined yesterday that the field begins in the
12	mid-1950s.
13	Probably the single the person who coordinated
14	most research about all the antidepressants and antipsychotics
15	was Jonathan Cole. He was the person who was entrusted by
16	Congress to coordinate research. Other people had applied to
17	him for grants to study things, so he was a very senior figure
18	in the field.
19	Q. All right. Let's look at one of the paragraphs in this
20	article that came out. What year was this, Doctor?
21	A. This is actually March 1990 or February 1990.
22	Q. Okay. Great. All right. This paragraph here says:
23	"A great deal has been written on the possible role
24	of serotonin in violence, suicide, and obsessive
25	behavior, and fluoxetine is known to be a potent and

	Healy – direct by Wisner 490
	490
1	selective serotogenic uptake inhibitor."
2	What does that mean, Doctor?
3	A. That, what they're referring to here is that there had
4	been issues from the point where there was a serotonin
5	hypothesis. Some people were saying in the 1960s that
6	serotonin was linked to people being depressed. That got
7	thrown out, but what happened during the 1970s in particular
8	is a few researchers with interest in this began to say that
9	low serotonin might be linked in particular to people being
10	impulsive and violent and going on to commit suicide and
11	becoming alcoholic, for instance.
12	Q. So it goes on, it says:
13	"Given this background, we were especially surprised
14	to witness the emergence of intense, obsessive, and
15	violent suicidal thoughts in these patients. Their
16	suicidal thoughts appear to have been obsessive as they
17	were recurrent, persistent, and intrusive. They emerged
18	without reason but were the patients' own thoughts. It
19	was also remarkable how violent these thoughts were. Two
20	patients fantasized, for the first time, about killing
21	themselves with a gun, and one patient actually placed a
22	loaded gun to her head. One patient needed to be
23	physically restrained to prevent self-mutilation.
24	Patient 2, who had no prior suicidal thoughts, fantasized
25	about killing himself in a gas explosion or a car crash."

Healy - direct by Wisn

This description by Dr. Teicher and Dr. Cole about this manifestation of suicidality, does that comport with your understanding?

A. It does. And there's two things, two or three things here
to quickly draw out. They're saying they came at this with no
expectation that this drug would cause these problems. Quite
the contrary, the expectation from prior research was maybe
these drugs were going to be particularly helpful in people
who were suicidal.

10 So that's why this was a big surprise to them, and 11 they were struck by the fact that it's not classic depressive 12 thinking. It seems to be different. It's -- they felt they 13 were witnessing a new phenomenon, and they also report a bunch 14 of this in the paper, but certainly the kinds of things 15 Jonathan Cole said when you talk to him, which is the patients 16 came back and said, "Gee, Doc, I've been depressed before, but 17 this was very different."

18 Q. Did this article cause a reaction from the Food and Drug19 Administration?

A. Well, it ultimately led to an FDA hearing in 1991. The
FDA were clearly -- anyone would be concerned about this.
These authors weren't saying these drugs should be banned.
Reporting what they were reporting, they were saying, look,
this is a thing that can happen to some patients. And the
expectation was, if we agree that it can happen, we can

	Healy - direct by Wisner 492
1	explore why it's happening and work out who it's safe to give
2	the drugs to and who might be at risk.
3	Q. Following the publication of the Teicher article, were any
4	of the manufacturers such as the defendant asked to submit a
5	suicide report?
6	A. I believe they were all asked to submit reports, yes.
7	Q. Draw your attention to Exhibit, Plaintiff's Exhibit 79,
8	Doctor. Let me know when you get there.
9	A. I'm here.
10	Q. All right. What is this document, Doctor?
11	A. This is what appears to be an email or a well, no, it's
12	actually a conversation record. I guess we didn't have email
13	in quite the same way back then. This is October 3rd, 1990,
14	it appears, and it's conversation with Martin Brecher,
15	Dr. Martin Brecher who is working in the FDA at that time.
16	Q. Who is Dr. Brecher in the context of the suicide issue?
17	A. He was one of the persons that was one of the people
18	who was reviewing, perhaps one of the authors, one of the main
19	reviews of the Paxil application that have gone into FDA,
20	looking at, does the drug work and what are the issues linked
21	to it.
22	Q. Would he have been someone who looked at the document a
23	second ago with the asterisks?
24	A. Yes. He I've seen that are comparable documents.
25	Q. Okay. And this document, Plaintiff's Exhibit 79, is it a

	Healy - direct by Wisner 493
1	document that you have reviewed in preparation for your
2	testimony?
3	A. Yes, it is.
4	Q. Is it something you relied on?
5	A. Yes.
6	Q. And would discussing its contents aid you in explaining
7	the suicide story to the jury?
8	A. Hopefully, yes.
9	MR. WISNER: Okay. At this time, your Honor,
10	permission to publish Exhibit 79 to the jury.
11	THE COURT: You may proceed.
12	BY MR. WISNER:
13	Q. All right. You mentioned this was a record of
14	conversation. Who is it a record of conversation between?
15	A. Well, it's a record of conversation between GSK and Martin
16	Brecher. The document gets signed at the bottom by Thomas
17	Donnelly, but clearly there may have been more people on the
18	conversation than just him.
19	Q. And what is your understanding of the purpose of these
20	documents?
21	A. Well, there's people there's a lot of back and forth
22	between companies and the FDA during the course of an
23	application. And that would lead to a lot of phone calls. It
24	may even lead to personal meetings. And the company will keep
25	a log of all these so that, you know, afterwards, people, if

	Healy - direct by Wisner 494
1	there are issues, can review what was actually said.
2	Q. So in this summary, who actually prepared or at least
3	did the FDA or did GSK prepare this summary?
4	A. This is the GSK summary. I don't know if anyone on FDA's
5	side would have been doing the same thing.
6	Q. Okay. Let's look at what it says. So in the first
7	paragraph under "Summary of conversation" let me get the
8	whole thing in there.
9	It says:
10	"Dr. Brecher called and initially mentioned that the
11	last submission was fine, and he looked forward to
12	receiving the weight gain response. He next said he was
13	calling to inform us of a concern that has arisen about
14	fluoxetine, and he is formally requesting that we prepare
15	a response to the same issues. He said that the public
16	press has been widely discussing the relationship between
17	fluoxetine and violence ideation and suicide thoughts.
18	Although the Division" I'll stop right there.
19	At this point, is Paxil on the market?
20	A. No, it's not.
21	Q. So what is he referring to when he talks about the public
22	press?
23	A. Well, it's about the Teicher article which seems to be
24	highlighting an issue that a lot of people around the place, a
25	lot of people who have been taking Prozac seem to be agreeing

	Healy – direct by Wisner 495
1	this happens to them. You've got a lot of patient groups
2	beginning to form saying, "Look, we think the Teicher article
3	is real."
4	Q. And who manufactures Prozac?
5	A. Lilly.
6	Q. Okay. It says here:
7	"Although the Division does not see it as a real
8	issue but rather a public relations problem, Lilly has
9	been asked to submit a detailed response to the public's
10	concern. He is, therefore, requesting that we do the
11	same since we have a drug with a similar mechanism of
12	action."
13	What does that refer to, "mechanism of action"?
14	A. He's saying that both these drugs are serotonin reuptake
15	inhibitors.
16	Q. Okay. He goes on to say:
17	"He said his request is not based on any concern that
18	has developed from his review of paroxetine but simply
19	that it is an issue that must be addressed with this
20	group of drugs."
21	Do you see that?
22	A. Ido.
23	Q. Now, this reference here to it not being a real issue but
24	a public relations problem, is that true?
25	A. Well, I a bit hard to comment on it. It's

1	Dr. Brecher is not clearly saying that it's FDA's view. It's	
2	very unfortunate phrasing. If it is FDA's view as opposed to	
3	Dr. Brecher's view, then it's terribly, terribly unfortunate.	
4	Q. Do you think suicide is a real issue, Doctor?	
5	A. I think suicide and treatment-induced suicide is a real	
6	issue and was since the 1950s, and to regard it as just a	
7	public relations issue would be unfortunate.	
8	Q. He goes on to say, "Dr. Brecher said that he is working	
9	full-time on the review of efficacy and expects to finish by	
10	the end of the year."	
11	What does that refer to?	
12	A. He well, as I repeated, to just repeat, the NDA, when	
13	it goes in, it's about whether the drug works or not, so he's	
14	looking in particular at the issue of, has the drug been shown	
15	to work.	
16	Q. All right. It goes on to say, he is not "He does not	
17	expect to have his time divided by any other drugs.	
18	Therefore, he would like us to submit this report by the end	
19	of November."	
20	Do you know what report he's referring to?	
21	A. Well, it's the updated report on, is there a suicide risk	
22	from Paxil.	
23	Q. Okay. Do you know if GSK ever did submit a report?	
24	A. They do.	
25	Q. All right. Let's turn to Exhibit, Plaintiff's Exhibit 82.	

	Healy - direct by Wisner 497
1	Do you have it?
2	A. Yes, I do.
3	Q. All right. What is Exhibit 82?
4	A. This is a letter from Thomas Donnelly who's written the
5	previous note we've just seen. In this case, he's writing to
6	Dr. Paul Leber who was the person who was the head of the CNS
7	division within FDA at that time, as I understand it. So he
8	was the person who was coordinating the input of all these
9	data. He was the person who would have been at this stage
10	Dr. Laughren's boss.
11	Q. Is there anything attached to the letter?
12	A. There is, yes.
13	Q. What is attached?
14	A. There is confidential proprietary material and the review
15	of suicidal ideation and behavior.
16	Q. Is this the report that we were just talking about that
17	was to be submitted?
18	A. Well, it's a report, and it looks like it was a report to
19	be submitted, yes.
20	Q. Is this a document that you relied upon in rendering your
21	opinions?
22	A. Yes, it is.
23	Q. And would talking about this document aid you in your
24	testimony today?
25	A. It would, yes.

	Healy - direct by Wisner 498
1	MR. WISNER: Your Honor, permission to publish.
2	THE COURT: You may proceed.
3	BY MR. WISNER:
4	Q. All right. So again, we have here, I just want to call
5	this out for reference. Who is SmithKline Beecham?
6	A. SmithKline Beecham is one of the forerunner companies of
7	GlaxoSmithKline. GlaxoSmithKline is a merger of Glaxo
8	Wellcome and SmithKline Beecham. That's where we get the name
9	GlaxoSmithKline from.
10	Q. And at this time, was SmithKline Beecham, the predecessor
11	to GSK, the ones controlling Paxil?
12	A. They were the company, yes, that had been handling Paxil.
13	Paxil comes from the SmithKline side of the company rather
14	than the Glaxo side.
15	Q. Got you. All right. Now, it says here in the letter
16	wrong paragraph. Do you see that paragraph right there,
17	Doctor? Can you read that to the jury?
18	A. I do, yes.
19	"To summarize in brief, this analysis of data from
20	prospective clinical trials in depressed patients clearly
21	demonstrates that patients randomized to paroxetine
22	therapy were at no greater risk for suicidal ideation or
23	behavior than patients who were randomized to placebo or
24	other active medication."
25	Q. What does that mean in regular terms?

Healy - direct by Wisner 499
A. What that's saying, the brief message from this report is
that there's no risk from Paxil.
Q. Okay. So let's go into the actual report itself. What
date was this submitted?
A. April 1991.
Q. Okay. Great. And this is titled what, Doctor?
A. It's looking at suicidal ideation and behavior, an
analysis of the paroxetine worldwide clinical database.
Q. All right. Let's go to the first table in the in the
document, but I want to make sure that I don't miss any
asterisks here. Okay. So I'm going to I'm going to do a
pretty big one. Can you still read it?
A. Yes, I can.
Q. Okay. I don't see any asterisks here. What is this
showing?
A. Right. Well, you'll see that most of the numbers are
just, I was saying, the active control numbers. There's more
patients from active control drugs here, but the Paxil number
of patients and the placebo number of patients are just the
same. And this is the people who have committed suicide.
Now, you didn't see you saw deaths before, and
there were 12 on Paxil. Now you're looking at suicides only.
Five of the 12 deaths were patients who committed suicide.
The same two deaths you saw on placebo before are now here
under the heading of patients who have committed suicide.

	500
1	You're also seeing a new a new thing introduced
2	which is PEY. That stands for patient exposure years.
3	Q. We'll get into the PEY in a minute, but let's focus on
4	that 2. Did those two patients commit suicide in the placebo
5	arm as indicated by the N 554?
6	A. No. We've been through this before. This didn't happen
7	in the placebo arm. This happened in the run-in phase.
8	Q. What's the difference between this table and the one we
9	saw before?
10	A. Well, one of the big differences is the missing asterisk.
11	The other difference is the placebo number are in. And the
12	third difference is we have a reference to PEY.
13	Q. All right. It goes on to say
14	MR. BAYMAN: Your Honor, I'd ask, for the rule of
15	completeness, that the jury be shown the paragraph, two
16	paragraphs up where it says, these occurred suicides
17	occurred during
18	MR. WISNER: Your Honor, he's testifying. He can
19	cross-examine. This is ridiculous.
20	MR. BAYMAN: I think the jury ought to be entitled to
21	see the page.
22	THE COURT: Well, it's subject to cross-examination.
23	I'm sure you'll call it to their attention.
24	Proceed.
25	BY MR. WISNER:

	Healy - direct by Wisner	
	501	
1	Q. All right. So the asterisk has disappeared. And then it	
2	says here what, Doctor?	
3	A. You mean	
4	Q. I have highlighted the sentence.	
5	A. "There were no substantive differences in the number or	
6	incidence of suicides among treatment groups."	
7	Q. Now, this 2 is supposed to be zero, right?	
8	A. Yes.	
9	Q. Okay. Is there a substantive difference between 5 and	
10	zero?	
11	A. Yes.	
12	Q. Is that sentence true?	
13	A. I don't believe it is.	
14	Q. Okay.	
15	THE COURT: Well, let's go back there. I'm not clear	
16	as to what you're saying.	
17	MR. WISNER: I'm sorry.	
18	THE COURT: The 2 put it up again. The 2 should	
19	be zero or 1?	
20	THE WITNESS: Zero.	
21	THE COURT: It should be zero. Okay. And if it's	
22	zero, then that changes the number on the other side?	
23	THE WITNESS: It will change after the 2, your	
24	Honor, you've got a percentage, so it's 0.36 percent, which	
25	gives you the impression that, in fact, there's more suicides	

	Healy – direct by Wisner 502
1	happening on placebo than on Paxil but, of course, if the
2	number is zero, then it's zero percent. So there's less
3	suicides happening on placebo than Paxil.
4	BY MR. WISNER:
5	Q. Let's go to the next table, Table 2. All right. What's
6	this table, Doctor?
7	A. This is again very similar, and just to stress, this is
8	the kind of stuff that the jury can be as expert on reading as
9	anyone like me. You've got the same numbers we've seen
10	before. You've got the missing asterisk although there is
11	text as Mr. Bayman has referred to.
12	And again, you've got the same figures we had before.
13	You've got the 40 and the 6. And again, there's a percentage
14	introduced which you saw in the previous table, and also
15	there's this PEY bit which for most jurors coming into this
16	not being used to it, they think, "What the hell is that?"
17	These days, you can Google these things, and you'll find it's
18	patient exposure years.
19	Q. And we will get into patient exposure years. Just stick
20	to the wash-outs for now. All right. So it says here that
21	there were six attempts of suicide in the placebo arms. Do
22	you see that, Doctor?
23	A. I do.
24	Q. Is that a factually true statement?
25	A. No. We've seen before from the previous document a year

	503
1	or two before that that 6 should really be 1.
2	Q. Okay. And if that 6 goes to a 1, how does that change the
3	relationship between placebo and paroxetine?
4	A. Well, again, it looks from the figures you're seeing that
5	there's no big difference between the two. You'd expect
6	actually that the Paxil data should be less than the placebo
7	data. That's what most people would have expected.
8	So to see anything even slightly bigger, 1.3 versus
9	1, is a little bit of a surprise, but if it drops down to just
10	1 and the figure of 1.1 drops down to 0.2, then we're into a
11	very big surprise.
12	Q. And it goes on to say again here, "No substantive
13	differences in the number or incidence of attempted suicides
14	were found among the paroxetine placebo or active control
15	groups." Is that true?
16	A. That's not true, no. And one of the other ways things
17	could have been handled would be to say that there were
18	four as I said, that there were over 4,000 patients in the
19	placebo group, and that would adjust the figures. And, you
20	know, and it would be interesting to see what the company
21	would have said then, but the best way to handle it is to just
22	stick strictly to the 554 patients who, after they were
23	randomized and after randomized, how many acts were there, and
24	that was 1. And if it's 1, then the statement below is
25	incorrect.

		504
to	the	
vc	ou see	2

1	Q. All right. Well, Mr. Bayman started reading into the
2	record other stuff. Let's actually look at it. Do you see
3	this paragraph right here, it says, "Of the three suicides
4	committed by patients randomized to the active control
5	requirements" actually, hold on. It's the paragraph before
6	that one.
7	A. Yes.
8	Q. Why don't you read it to me, Doctor, since you're the
9	expert.
10	A. Well, it's the kind of thing that the jury will be as
11	expert on reading as I am but:
12	"Of the two suicides committed by patients randomized
13	to placebo, the method by which they took their lives was
14	unknown. Although these patients were actually
15	participating in an active control study, the acts of
16	suicide were committed during the participation in the
17	placebo run-in phase. The specific points in time at
18	which these individuals took their lives were two days
19	and seven days prior to the baseline evaluation."
20	Q. Why do they have negative 2 and negative 7 in there?
21	A. Well, that's saying, you know, what would happen is, on
22	the trial, once you go on the active treatment, they'd be
23	looking at day one or day two or day ten. You'd see it, day
24	ten without a plus before it. Minus before it means this
25	happens before the trial proper begins.

	Healy – direct by Wisner 505	
1	Q. All right. So this is discussing the actual two completed	
2	suicides, right?	
3	A. Yes.	
4	Q. The zero to five, right?	
5	A. Uh-huh.	
6	Q. I'm looking at the next page under "Attempted suicides."	
7	Does it mention anything about the run-ins there?	
8	A. Well, I can't see it there.	
9	Q. Read through that paragraph and tell me if you see	
10	anything.	
11	A. No, I can't.	
12	Q. So there's no asterisk and there's no discussion at all	
13	about the five or the six suicide attempts being in the	
14	run-in	
15	A. Well, it isn't just in that.	
16	Q. Where else is it?	
17	A. I'm unsure. I'm not saying it is.	
18	Q. Okay.	
19	A. It's just both the jury and I can see that it's not in	
20	this.	
21	Q. Okay. So it's not in this section called "Attempted	
22	suicides." I'll go to the next page. It goes on to suicide	
23	attempts by overdose in patients randomly do you see that,	
24	Doctor?	
25	A. I do, yes.	

	Healy - direct by Wisner 506	
1	Q. That's not what we're talking about here. The next	
2	section is suicide attempts other than overdose in patients	
3	randomized. Do you see that?	
4	A. I do, yes.	
5	Q. All right. Is there anything in there about that?	
6	A. Not that I'm aware of it.	
7	Q. It says well, let's take a look at these. It's sort of	
8	interesting. It says, 12 patients who had received paroxetine	
9	therapy attempted suicide by methods other than overdose. The	
10	following methods were reported: Lacerations. What's a	
11	laceration?	
12	A. When you cut your wrists or throat or whatever.	
13	Q. Poisoning, what's that I mean, we know what that is.	
14	Defenestration, what's that?	
15	A. It involves usually jumping out through windows.	
16	Q. There's a word for jumping out of a window?	
17	A. Yes.	
18	Q. All right. Hanging?	
19	A. Well	
20	Q. And one method unknown. Do you see that?	
21	A. Yes.	
22	Q. All right. I've gone through several pages here. We're	
23	now in the Hamilton Depression Scale section, and I haven't	
24	seen any mention of the run-ins. Have you seen any?	
25	A. Well, I've seen loads and loads of documents. I'm going	

Healy - direct by Wisner

1 to trust you that it's not here. I amn't aware of it being here, but just as I sit here right at the moment, I can't 2 3 absolutely swear to the jury that it's not, but I think it's 4 not. 5 Q. How would you have to go about figuring out whether or not 6 those five of six suicide attempts ascribed to placebo 7 actually happened in the run-in? What would you have to do? 8 A. You would have had to see the previous document. That 9 would have had -- that would have alerted you to what was 10 going on. It's not clear from just this document, but the one 11 we looked at previously where they listed six and it turns out actually to be one, you'd have to know about that. 12 13 Q. And if someone was just cursorily reading this like it 14 wasn't a real issue, would it be easy to miss the data? MR. BAYMAN: Objection. It calls for speculation, 15 16 your Honor. 17 THE COURT: Sustained. 18 BY MR. WISNER: 19 Based on your experience as a person who's dealt with Q. 20 people --21 Α. Well --22 Q. Let me ask the question. Let me ask the question. Based 23 on your experience, do you believe it would be easy for you to 24 miss that? 25 A. Well, I think even people like Michael Teicher who came

	Healy - direct by Wisner 508
1	out, most people came from a background
2	MR. BAYMAN: Your Honor, it is not Martin Teicher and
3	how he would react. The question was asked to Dr. Healy.
4	THE COURT: Confine yourself to your thoughts.
5	THE WITNESS: Yes. Sure.
6	At that time, the expectation was that these drugs
7	wouldn't cause a problem. So people without expectation, that
8	would included me back then, would have would have missed
9	it. If there wasn't anything there, we wouldn't have had any
10	reason to doubt the 6. We would have thought, that's probably
11	the right number.
12	BY MR. WISNER:
13	Q. All right. All right. I want to go back to the suicide
14	language. I just want to review this where it says, do you
15	see this sentence right here, Doctor, "There were no
16	substantive differences in the number of incidence of suicides
17	among treatment groups." Do you see that?
18	A. Yes.
19	Q. And then we have almost identical language right here. Do
20	you see that?
21	A. Yes.
22	Q. All right. Why don't you turn to Exhibit 28.
23	A. Yes. I'm here.
24	Q. All right. What is document 28?
25	A. This is a summary basis of approval document.

	Healy - direct by Wisner 509	
1	Q. What is that document?	
2	A. Well, that's a document again looking at the FDA review of	
3	the data that has come in to them from GSK.	
4	Q. Okay. And is this the document that precedes a drug's	
5	approval?	
6	A. Yes. The FDA will write out to the company, "We approve,	
7	you'll be able to claim your drug works as an antidepressant,"	
8	and this will be the background document to the letter that	
9	FDA writes.	
10	MR. WISNER: Your Honor, this document has already	
11	been admitted into evidence. Permission to publish.	
12	THE COURT: Yes. You may proceed.	
13	BY MR. WISNER:	
14	Q. Okay. Now, Doctor, we have here the screen shot from the	
15	prior exhibit. Okay?	
16	A. Yes.	
17	Q. All right. I want you to turn to Page 29 in Exhibit in	
18	Exhibit 28. Turn to Page 29 in Exhibit 28.	
19	A. I think I have that, yes.	
20	Q. Are you there on Page 29?	
21	A. Yes, I think so.	
22	Q. All right. I'm going to show the jury in a second, but I	
23	just want you to read it. Read the last paragraph there.	
24	Read the second sentence.	
25	A. This is where I'm going to have to put on my glasses	

		Healy - direct by Wisner 510
1	beca	ause it's reasonably small print here.
2		"The incidence is expressed as cases per patient
3		exposure year, brackets, PEY, where total PEYs are equal
4		to the sum of the duration of treatment for each patient,
5		brackets, in days, divided by 365."
6	Q.	I actually gave you the wrong sentence to read.
7	Α.	Sorry.
8	Q.	That was a pretty complicated one. Why don't you read the
9	nex	t sentence.
10		THE COURT: Why don't you put it up on the board.
11	BY I	MR. WISNER:
12	Q.	Sure. Read the next sentence, Doctor.
13	Α.	"There were no substantive differences in the number or
14	inc	idence of suicides or suicide attempts among treatment
15	gro	ups."
16	Q.	That is nearly verbatim from what's in the suicide report?
17	Α.	It is, yes.
18	Q.	Okay. And this is the FDA's report?
19	Α.	Yes.
20	Q.	All right. After GSK submitted the suicide report in
21	199 ⁻	1, did it actually try to make the data available or
22	pub	lish it?
23	Α.	The data appeared in a range of different articles, yes.
24	Q.	Are you familiar with Dr. Dunbar?
25	Α.	Yes, I am familiar with Dr. Dunbar.

	Healy – direct by Wisner 511	
1	Q. Are you aware that his deposition has already been played	
2	in this case?	
3	A. I am aware that part of his deposition has been played,	
4	yes.	
5	Q. Okay. And are you aware of whether or not he published	
6	data based upon this suicidality report?	
7	MR. BAYMAN: Your Honor, this is cumulative. They've	
8	heard from Dr. Dunbar.	
9	MR. WISNER: I'm just laying foundation.	
10	THE COURT: I haven't heard the question, sir.	
11	BY MR. WISNER:	
12	Q. I said, are you aware if he published data relating to it?	
13	A. Yes, he did. It was more than one article.	
14	Q. Okay. Please turn to Exhibit 34 in your I'm sorry,	
15	Doctor. I think I went ahead too quickly. Can you turn to	
16	Table 55 in I'll get it up on the screen, 55 in the FDA	
17	summary basis of approval. So it's the exhibit we were just	
18	looking at. It's No. 28.	
19	A. Yes. And you want me to look at?	
20	Q. Turn to the second-to-last third-to-last page, Table	
21	55.	
22	MR. BAYMAN: Your Honor, this is cumulative. The	
23	jury has heard Dr. Dunbar read from the article and be asked	
24	the very same questions by videotape yesterday. This is	
25	entirely cumulative.	

Healy - direct by Wisner 512 1 MR. WISNER: We're talking about the FDA report, not about Dunbar right now. I went back. Sorry. 2 3 MR. RAPOPORT: They haven't seen 55 yet. THE COURT: Table 55? 4 5 MR. WISNER: In the summary basis of approval. This is not about Dunbar. 6 7 MR. RAPOPORT: Yes, your Honor. This is the FDA's 8 version. 9 MR. WISNER: Yes. This is the FDA document. 10 BY MR. WISNER: 11 Q. All right. Doctor, do you have Table 55? 12 A. I do, yes. 13 MR. RAPOPORT: Wait. 14 MR. WISNER: Oh, I'm sorry. May I proceed, your 15 Honor? THE COURT: Yes. 16 BY MR. WISNER: 17 Q. Okay. All right. What is Table 55, Doctor? 18 19 A. Well, this again gives you the data on the suicides and 20 the suicidal acts which we have seen before. It's pretty much 21 the figures that we've seen earlier. 22 Q. Well, Doctor, you said "pretty much." Let's actually look 23 at them. It has placebo. Do you see that? 24 A. Yes, I do. 25 Q. And under "suicide," it has how many suicides in the

	Healy – direct by Wisner 513	
1	placebo arm?	
2	A. Two.	
3	Q. Is that true?	
4	A. No.	
5	Q. Is that a copy and paste from the suicide report?	
6	MR. BAYMAN: Objection, your Honor. That calls for	
7	speculation. This is an FDA document.	
8	THE COURT: Yes. Sustained.	
9	MR. WISNER: Fair enough. I just meant, is that a	
10	copy, a verbatim	
11	THE COURT: "Is it the same."	
12	BY MR. WISNER:	
13	Q. Thank you. Is it the same?	
14	A. It is, yes.	
15	Q. All right. Sorry. It's been a long couple of days.	
16	Okay. Attempted suicides, the data there, do you see that?	
17	A. Yes.	
18	Q. And then you have attempted, total attempted suicides.	
19	You have a number here. I actually have it highlighted	
20	incorrectly. Do you see that, 6?	
21	A. Yes.	
22	Q. Were those all in the placebo group?	
23	A. Well, they weren't actually. They've been represented as	
24	being in at the placebo group, but they weren't.	
25	Q. And that's the same as the '91 suicide report?	

	Healy - direct by Wisner 514
1	A. Yes.
2	Q. Doctor, I are there any asterisks on this page?
3	A. No.
4	Q. Is there any statement about these suicides being from the
5	wash-out periods?
6	A. No.
7	Q. Any statement that they didn't occur in the placebo arm?
8	A. No.
9	Q. Thank you. All right. Let's move on to Exhibit 34 like I
10	had asked you about. Now, I asked you earlier if GSK ever
11	published any literature conveying the data we were just
12	looking at, right?
13	A. Yes.
14	Q. Look at Exhibit 34. What is that?
15	A. Well, this is this is a brief abstract of an article by
16	Dunner and Dunbar. And it says, "Reduced suicidal thoughts
17	and behavior, brackets, suicidality, with paroxetine"
18	presented at the American College of
19	Q. We don't have it up yet, Doctor. I just want you to tell
20	me what the document is.
21	A. It's an abstract of a presentation that was made, and the
22	abstracts usually give the key features.
23	MR. WISNER: Okay. Your Honor, permission to publish
24	Exhibit 34 to the jury. It's already been admitted into
25	evidence.

	Healy - direct by Wisner 515
1	THE COURT: You may proceed.
2	MR. BAYMAN: Your Honor, I don't object to it, but
3	it's cumulative. The jury has heard the very author of the
4	article by videotape yesterday get asked these very same
5	questions.
6	THE COURT: We didn't have the article yesterday.
7	That was the problem. Remember, there were some objections
8	about the exhibits and, therefore, I said go ahead since we
9	hadn't had that aspect resolved. So I'll let him go back to
10	it and clear it up just as I'll let you do that as well.
11	MR. BAYMAN: Okay. Thank you.
12	BY MR. WISNER:
13	Q. All right. Doctor, so this is a packet. On the first
14	page, it has it's hard to read, but do you see it says
15	"Paxil"?
16	A. Yes.
17	Q. And it says, "annotated bibliography."
18	A. Yes.
19	Q. What does that refer to?
20	A. Well, again, this is a bunch of articles or other
21	published material on Paxil. It's the kind of documents that
22	a company like GSK might give to doctors who might be thinking
23	about prescribing Paxil, or they might give them to their
24	sales representatives to hand out to doctors.
25	Q. And so who prepared this compilation? Was it

	Healy - direct by Wisner 516
1	A. This would have been prepared by SmithKline Beecham as
2	they were then.
3	Q. Okay. All right. So then we have an annotated
4	bibliography. On Page 27 of this document, there's a
5	reference to Dunner and Dunbar. Do you see that?
6	A. I do, yes.
7	Q. And the title, you already read the title to the jury, it
8	says, "Reduced suicidal thoughts and behavior, suicidality,
9	with paroxetine." And it goes on to read, "Presented at the
10	American College of Neuropsychopharmacology, December 1991,
11	San Juan, Puerto Rico."
12	What is the American College of
13	Neuropsychopharmacology?
14	A. The American College of Neuropsychopharmacology is the
15	premiere body in the United States for looking at issues to do
16	with psychotropic drugs, the antidepressants, the
17	antipsychotics, issues ranging from brain research through to
18	clinical research.
19	The British corresponding group would be the British
20	Association for Psychopharmacology, of which I was the
21	secretary at one point.
22	Q. Now, is the is it also known as the ACNP?
23	A. Yes.
24	Q. Is the ACNP a prestigious organization?
25	A. Very, yes. In terms of the use of drugs, ACNP would be

Healy - direct by Wisner

1	regarded as the people who know about these things as opposed
2	to the American Psychiatric Association. They're doctors but
3	they include therapists and people who do all sorts of other
4	things or have expertise in other things than just drugs.
5	These are the people who identify as being the experts on the
6	drugs.
7	Q. Now, it says it was presented. What does that mean?
8	A. Well, it means that it could have been either presented as
9	an oral presentation, or it could be presented as what's
10	called a poster where the materials, the kinds of tables
11	you're seeing, would be presented to an audience, and someone
12	like Dr. Dunbar or Dunner would be there to talk to anyone who
13	came up and was interested to ask about the issues.
14	Q. All right. Let's read what it says here well, it talks
15	about what happens, but I want to actually get to the punch
16	line. It says here:
17	"Suicides and suicide attempts occurred less
18	frequently with paroxetine than either placebo or active
19	controls. Paroxetine was also significantly superior to
20	placebo and active controls on most measures of emergence
21	of suicidal thought. This analysis shows that
22	suicidality is inherent in depressive illness and that
23	antidepressant therapy with paroxetine is appropriate for
24	the integrity of depressed patients."
25	In non-doctor terms, what is that saying?

	Healy - direct by Wisner 518
1	A. That's saying that, "Our drugs don't cause the problem,
2	the illness causes the problem, and the key thing is to make
3	sure you get people who are depressed on antidepressants like
4	Paxil."
5	Q. Wait a second, Doctor. I understand it's one thing to say
6	we don't know if it causes suicidality, but this is saying
7	that it actually reduces suicidality?
8	A. That's what it's saying and
9	MR. BAYMAN: Objection to leading.
10	THE WITNESS: that's
11	THE COURT: Yes, you're leading.
12	BY MR. WISNER:
13	Q. Fair enough. Do you have an opinion about what this is
14	telling doctors?
15	A. Yes, I do, which is that whatever you've heard about the
16	fuss that's been happening out there about these drugs causing
17	a problem, you should be reassured, our view is the drug isn't
18	causing a problem and that actually you're going to do more
19	harm than good if you stop using the drug.
20	Q. Now, if you're a practicing physician and you get handed
21	an article from a prestigious organization like ACNP, how does
22	that affect the way you treat a patient who you're treating
23	with Paxil?
24	A. Yes, it will make you more likely to use the drug and
25	dismiss the concerns that may be out there as coming from a

	Healy - direct by Wisner 519
1	fringe group or whatever.
2	Q. Well, let's say your patient starts having a reaction, an
3	akathisia-type reaction. Seeing this, what does a physician
4	do?
5	A. Doubled
6	MR. BAYMAN: Objection, calls for speculation.
7	BY MR. WISNER:
8	Q. I'll rephrase, your Honor. Seeing this, what would you
9	do?
10	A. Well, seeing this, if I believed this at that time, I
11	would have doubled the dose of the pills.
12	Q. And what would doubling the dose to a person who's already
13	taking the drug and is having a reaction do?
14	A. It may kill them.
15	Q. Do you know if Dr. Dunbar has ever sought to retract his
16	publication?
17	A. Not that I'm aware of. I've seen a range of different
18	points where he says, our drug actually reduces the risk. I'm
19	not aware of him ever saying anything to the contrary, not
20	even coming back to the point where, you know, that the drugs
21	may be neutral as regards to risk.
22	Q. Now, Doctor, was it appropriate for GSK to have used that
23	run-in data in assessing the suicide risk?
24	MR. BAYMAN: Objection, company conduct, your Honor.
25	THE COURT: Overruled.

	Healy - direct by Wisner 520
1	BY THE WITNESS:
2	A. It's not appropriate. It breaches regulations. The
3	regulations say you should be counting from baseline, not from
4	entry, from baseline.
5	MR. BAYMAN: Your Honor, he's now testifying as an
6	FDA regulatory witness. This is beyond the scope of his
7	expertise. Move to strike.
8	THE COURT: Well, you can inquire as to, when you use
9	the word you haven't established the use of the word
10	"regulations."
11	MR. WISNER: Yeah. Let's not
12	THE COURT: In that sense, I sustain your objection.
13	MR. BAYMAN: Thank you, your Honor.
14	BY MR. WISNER:
15	Q. Dr. Healy, let me ask you this question: Based on, you
16	know, basic scientific principles, was it scientifically
17	legitimate to count the pre-baseline suicide attempts?
18	A. No, it's not. It would be scientifically legitimate to
19	explore what happens during the baseline period, but it's not
20	legitimate to include it in the placebo figures.
21	
21	Q. Now, Doctor, have you seen any documents from within GSK
22	Q. Now, Doctor, have you seen any documents from within GSK itself acknowledging that fact?
22	itself acknowledging that fact?

	Healy - direct by Wisner 521
1	A. I was about to say that I can't find it, all your efforts
2	to keep me on track here had failed, but I have found it.
3	Q. You found it?
4	A. Yes.
5	Q. Okay. Great. What is this document, Doctor?
6	A. Now, this is a note from Daniel Burnham to a number of
7	colleagues within GSK.
8	Q. Is this a document that you reviewed in preparing your
9	testimony today?
10	A. Yes, it is.
11	Q. Is this a document that you believe discussing would help
12	your testimony today?
13	A. I believe it would.
14	MR. WISNER: Okay. Can we switch it's actually
15	already here. It's actually already here. Your Honor,
16	permission to publish. This has already been admitted into
17	evidence.
18	THE COURT: All right.
19	MR. WISNER: Unfortunately, it's not in my iPad
20	because it got corrupted, so I'm going to have to use the old-
21	fashioned method.
22	THE WITNESS: I'm pleased that it's not in your iPad.
23	I prefer the old style of doing things.
24	BY MR. WISNER:
25	Q. Okay. All right. So, Doctor all right. Doctor, who

	Healy - direct by Wisner 522	
1	is Daniel Burnham?	
2	A. Well, he's a person who works in GSK at that point in	
3	time. I'm sure at one point, I'll have known just what he	
4	did, but as I sit here today, I can't tell the court just	
5	exactly what his role was.	
6	Q. Okay. But he was a physician within GSK; is that right?	
7	A. That's my understanding.	
8	Q. All right. And he has an email here that he sent to a	
9	couple of different people. Do you see that?	
10	A. I do.	
11	Q. And the subject is what?	
12	A. It's, "Incidence of death and suicide in paroxetine	
13	randomized controlled trials in depression, FDA request."	
14	Q. And what is the date of this email, Doctor?	
15	A. November 1998 '9. Sorry, '9.	
16	Q. So that Dunham article we were talking about, that was	
17	published when?	
18	A. That was 1991.	
19	Q. Okay. So now we're, what, how many years later?	
20	A. Two years later.	
21	Q. This is 1999, Doctor.	
22	A. Yes.	
23	Q. Two years later?	
24	A. Is the Dunbar one let's go back.	
25	Q. Yes. Let's take a look at that.	

Healy - direct by Wisner 523 The Dunbar one is 2001. 1 Α. So that would be how many years later, this email? 2 Q. 3 Α. Two years later. 4 MR. BAYMAN: No, that's wrong. THE COURT: '91. 5 MR. WISNER: 1999, 1991. 6 7 THE WITNESS: Oh, sorry. 8 THE COURT: '91. 9 THE WITNESS: Sorry. Well, hang on a second. No. Dunner is 1991. This isn't later. This is later than the 10 11 Dunner one, so this is eight years later. This is eight years 12 after the Dunner and Dunbar. Sorry about that. BY MR. WISNER: 13 14 You might have thought I said '89. I apologize. Q. 15 No, no, no. Actually, all the problems were at my end. Α. Ι 16 haven't had quite enough coffee. 17 All right. So what's Dr. Burnham talking about? What's Q. 18 his concern that he's raising here? 19 MR. BAYMAN: Your Honor, it's not -- objection. Ι 20 let it go before, but he's not a physician. 21 MR. WISNER: Oh, I'm sorry. 22 THE COURT: Who isn't a physician? 23 THE WITNESS: Dr. Burnham. MR. BAYMAN: Burnham is not a physician, your Honor. 24 25 And Mr. Wisner said that earlier and I let it go but now --

	Healy - direct by Wisner 524
1	MR. WISNER: I thought he was a Ph.D.
2	THE COURT: Oh, Burnham is not.
3	MR. BAYMAN: He's not a physician.
4	MR. WISNER: I though he is a Ph.D., though.
5	MS. HENNINGER: That's not in evidence.
6	BY MR. WISNER:
7	Q. All right. Mr. Burnham is at GSK?
8	A. Well, if he's a Ph.D., then he is Dr. Burnham, but he
9	wouldn't be a medical doctor.
10	Q. Okay. Well, let's just move through this. We'll call him
11	Mr. Burnham so we don't mess create any problems.
12	THE COURT: We'll call them all doctors.
13	BY MR. WISNER:
14	Q. All right. So it says here:
15	"The two suicides among the 544 placebo patients in
16	Montgomery and Dunbar's 1995 publication actually
17	occurred during the placebo, the single-blind placebo
18	run-in, not double-blind placebo. Because patients
19	undergo usually one week of single-blind run-in before
20	randomization, these two suicides on placebo are not
21	comparable to deaths occurring after randomization for
22	three reasons."
23	Do you see that, Doctor?
24	A. I do.
25	Q. And Mr. Burnham lists these three reasons why that was

	Healy - direct by Wisner 525
1	inappropriate?
2	A. He does.
3	Q. And then he goes:
4	"Bottom line, we must mention the placebo run-in
5	deaths to reconcile the overall incidence figures with
6	the Montgomery and Dunbar publication. However, we
7	cannot combine these placebo run-in deaths with the
8	randomized placebo death rate for the three reasons
9	above. Thus, we are left with a .1 percent suicide rate
10	on paroxetine IR and a zero percent rate on placebo."
11	A. Yes.
12	Q. What does that mean, Doctor?
13	A. Well, it means that there's a recognition here that the
14	way things were presented earlier isn't appropriate and we
15	need to reorganize how we're going to present the material.
16	Q. Now, did GSK, following this email, immediately publish a
17	retraction of the Dunbar material?
18	A. Not that I'm aware of.
19	Q. Do you know if GSK continued to hand out the Dunbar article?
20	A. They may well have done, but I'm not sure.
21	Q. Okay. All right. Doctor, just so to remind you, we're
22	still talking about the wash-out problem. We've got 13 things
23	to cover. They'll get much faster after this.
24	A. Yes.
25	Q. But do you know if following the realization of this

	Healy - direct by Wisner 526
1	error, GSK ever went back and reanalyzed the data?
2	A. They did.
3	Q. Do you know what year that was?
4	A. I believe the next iteration of the data is around 2002.
5	Q. Okay. Do you know what they were doing in the time in
6	between?
7	A. Well, there was again, there's a lot of back and forth
8	between the regulators and companies, not just GSK, on these
9	issues. And there was a view that maybe the data shouldn't be
10	handled the way they had been handled and that it might be
11	appropriate to just consider placebo-controlled data.
12	Q. Now, at this point prior to 2002, were you out speaking
13	out about whether or not Paxil could cause suicide?
14	A. I was saying that the SSRIs can come with a problem. I
15	didn't specifically single out Paxil.
16	Q. Prior to 2002, you never specifically addressed Paxil,
17	Doctor?
18	A. Well, I've said the problem can come from these drugs
19	generally, Paxil included.
20	MR. WISNER: Okay. Please turn to Exhibit 16.
21	This also, your Honor, has been admitted into
22	evidence. Permission to publish.
23	THE COURT: Proceed.
24	BY MR. WISNER:
25	Q. Do you have Exhibit 16 in front of you, Doctor?

	Healy - direct by Wisner 527
1	A. I do, yes.
2	Q. All right. This is an email we've discovered in
3	litigation.
4	What year is it dated?
5	A. This is dated 2001.
6	Q. And what year in 2001?
7	A. Sorry. What month?
8	MR. BAYMAN: Your Honor, can I ask that that comment
9	be stricken, he discovered in litigation?
10	THE COURT: Yeah. That may go out.
11	MR. WISNER: Oh, I'm sorry.
12	MR. BAYMAN: Thank you.
13	MR. WISNER: This document sorry, your Honor.
14	BY MR. WISNER:
15	Q. So it reads well, it's from Bonaventure Agata. Do you
16	see that?
17	A. Yes, I do.
18	Q. Do you recognize any of the people on this?
19	A. Well, yes. There's some senior GSK people here.
20	Q. Can you point one out for me?
21	A. Barry Brand is one, for instance.
22	Q. Do you know what department Barry Brand worked in?
23	A. No. As I sit here today, I'm tempted to say marketing,
24	but I'm not sure.
25	Q. Okay. It goes on:

1	"Paul/David, these suicide reports seem to be
2	appearing too often for comfort. Would it be possible to
3	do possible to do identify through meta analysis the
4	incidence of suicide/homicide when patients have been on
5	Paxil versus general population versus patients on other
6	antidepressants versus depressed patients in general?
7	This is a potentially this is potentially an area in
8	which competitors are likely to capitalize on once the
9	lawyers have finished their work in the courts."
10	What does it mean to what is it talking about
11	competitors capitalizing on?
12	A. Well, the worry being expressed here is that a perception
13	may be generated that Paxil is worst in class so that other
14	SSRI companies would perhaps say
15	MR. BAYMAN: Your Honor, this is now calling for
16	speculation. He's
17	THE COURT: Sustained.
18	MR. BAYMAN: Thank you.
19	THE COURT: Sustained.
20	MR. BAYMAN: And I move to strike his prior
21	THE COURT: It may go out.
22	MR. BAYMAN: Thank you.
23	BY MR. WISNER:
24	Q. Well, the next sentence reads, "It would, therefore, be
25	prudent to have a publication ready." Do you see that,

	Healy - direct by Wisner 529
1	Doctor?
2	A. I do.
3	Q. Following this email in 2001, did GSK go ahead and prepare
4	a document to respond to the suicide data?
5	A. They did.
6	Q. Is that the data that reanalyzed the data from 20' from
7	1989?
8	A. Yes.
9	MR. BAYMAN: Objection. That's just not demonstrated
10	by the evidence, your Honor. I move to strike.
11	THE COURT: That may stand. Proceed. Subject to
12	cross-examination.
13	BY MR. WISNER:
14	Q. All right. Doctor, we're going to move on to, we were
15	talking about these 13 ways GSK hid the signals. We've talked
16	about the wash-out data. Let's move on to the next one. Do
17	you want to do you want the list in front of you? I know
18	you created it.
19	A. What is the exhibit number again? 34, something, wasn't
20	it?
21	Q. Sounds about right. It was I believe it was 34 or
22	36.
23	THE COURT: 36.
24	THE WITNESS: 36.
25	MR. WISNER: Yes.

	Healy – direct by Wisner 530
1	THE COURT: This is not in evidence, counsel.
2	MR. WISNER: They're not in evidence, and I'm not
3	showing it to the jury.
4	THE COURT: All right.
5	THE WITNESS: Yes. Okay.
6	BY MR. WISNER:
7	Q. Okay. So we covered the wash-out data. What's the next
8	way GSK hid the signal?
9	A. This is the PEY you've seen, the patient exposure years.
10	Q. All right. What is patient exposure years? How is that
11	used in a suicide risk analysis?
12	A. Okay. Let me explain this to the court quickly. The
13	easiest way to explain it is perhaps this. I'm sure all of
14	you and certainly I can remember when the space shuttle blew
15	up leaving the earth and also when one blew up coming back to
16	earth.
17	You can count the risk of the space shuttle by the
18	number of astronauts that have gone up into orbit and the
19	number that have ended up dead. That's just the number of
20	deaths per trip. Or you can count the number of deaths per
21	mile.
22	Now, if you count the number of deaths per mile ${f I}$
23	mean, if you look at the number of deaths per trip, the space
24	shuttle is a very dangerous way to travel. If you look at the
25	number of deaths per mile, it may be the safest form of travel

on earth or in the universe because there are hundreds of
 thousands of miles that they actually cover, and the number of
 deaths per mile is actually extremely low.

4 So from that point of view, there's two different The standard way to look at adverse events is the 5 ways. 6 number of deaths per trip. And in particular, the space 7 shuttle is very good for this one because everybody had always 8 felt that the risks of an antidepressant are when you go on 9 the drug -- when you're leaving the earth's atmosphere -- and 10 when you come back in, when you come off the drug. They're 11 the two risky periods.

When you're on the drug, if the drug suits you, you could be there for years on the drug circling around quite happy and at no risk at all. So if you count in all the years where the people who are the selected group who are happy on the drug get mixed in with the people who are the ones at risk, you can dilute the risk to make the drug look terribly safe.

FDA usually -- the usual way to count adverse events was the number of events per trip. FDA has said -- I mean, they said later that you can also use exposure years, but it shouldn't be the main thing you use. There are certain adverse events that it may be important for. There are certain adverse events that only start happening when you've been on a drug for a few years. That's where it may be

	Healy – direct by Wisner 532
1	important. But it's not a useful technique for problems that
2	happen going on the drug and coming off it.
3	Q. All right. Let's go back to Exhibit 82 which is the
4	which is the suicides report from 1991.
5	A. Yes.
6	Q. All right. Let's look at the attempted suicide rate here
7	on Table 2. Have you got it?
8	A. Yes, I have.
9	Q. All right. Show us where the and you can actually
10	touch the screen, Doctor, and it should show up.
11	A. Yes.
12	Q. Where is the PEY in here?
13	A. Okay. It's just ah, this is new to me. This is the
14	first time I've played with this machine.
15	Q. Okay.
16	A. Anyway.
17	Q. And then where is the PEY for paroxetine?
18	A. It's over here.
19	Q. Okay. Great. And I see that there's 1008 PEY for
20	paroxetine and 72 for placebo.
21	A. Yes.
22	Q. What does that mean?
23	A. What happens here is nobody in these trials stays on
24	well, very few people stay on placebo for a long time.
25	They're just in for a six-week trials, so they don't

	533
1	accumulate a lot of years safely on placebo.
2	But in some of the paroxetine trials, it's not just
3	the six-week period. Some of them have an extension arm, so
4	the patient can remain on treatment for months or years
5	afterwards. And this is appropriate. I mean, that's not a
6	bad thing to be doing if you want to look at the safety of the
7	drug.
8	But counting all of those patients who only remain on
9	treatment because they're doing quite well, counting every
10	single week they're on treatment can be inappropriate when
11	you're adding it in to a problem like this.
12	Q. So we have here the placebo number, and we have the PEY
13	number. Do you see that?
14	A. Yes.
15	Q. And what's the difference between those numbers?
16	A. Well, there's a much bigger difference between the patient
17	exposure years on Paxil compared with the patient exposure
18	years on placebo than there is between the number of patients
19	on Paxil and the number of patients on placebo.
20	Q. It's double for placebo; is that right?
21	A. How do you mean?
22	Q. Well, it's .0
23	A. Oh, you mean the actual figures?
24	Q. Yes.
25	A. Down the you're asking me to look at the actual yes.

Healy - direct by Wisner

1	When you get when this happens, you transform the picture.
2	And if you see on the bottom line here, when you do this, if
3	you're doing the figures by patient exposure years, it looks
4	like Paxil only poses half the risk placebo poses. That is,
5	not only is it not causing a problem but it's actually
6	preventing a problem.
7	Q. Well, Doctor, that patient exposure years, is that
8	actually including the run-ins as well?
9	A. In this case well, what's happening, it's not including
10	the run-in we can do. They aren't added in here. But what's
11	happening is, you have two things going on at the same time.
12	One is including the run-in suicidal acts and using patient
13	exposure years.
14	So there are two different things here that are
15	making the problem seem less, not only making the problem seem
16	less but actually turning it into an issue about the drug
17	being protective rather than risky.
18	Q. Okay. I've got to clear it up here.
19	All right. Doctor, that was the second one that was
20	used in the PEY, or patient exposure years. What's the third
21	way you can hide the signal?
22	A. I'm sure the jury are pleased and I'm pleased that we're
23	moving through these things a bit quicker now.
24	Q. You should just pull it out and set it aside.
25	A. Yes. Using Studies 057 and 106.

	Healy – direct by Wisner 535
1	Q. Okay. What does it mean when a study has a number? What
2	is that?
3	A. That well, all of the trials that are done by all of
4	the companies will have a protocol number. So it's a way for
5	people to be able to identify the trial afterwards.
6	Q. And what is Study you said two studies. What are they?
7	A. 057 and 106.
8	Q. Were these studies somehow different than the other types
9	of studies that GSK did?
10	A. Very different.
11	Q. How so?
12	A. Well, they were done in a different patient population,
13	and they have a completely different profile of adverse events
14	as regards patients being suicidal than the major depressive
15	disorder trials did.
16	Q. And what's the difference?
17	A. Well, what you're looking at is 056 and 057 and 106
18	were done on patients that GSK call intermittent brief
19	depressive disorders, other people have called recurrent brief
20	depressive orders, and other people have called borderline
21	personality patients.
22	And these are patients who have multiple suicide
23	attempts regularly. I mean, long before treatment, this is
24	nothing to do with treatment, they just have multiple suicide
25	attempts.

And this is the kind of patient group that, you know, you might have thought an SSRI, if they were anti-suicidal, could help, you know. So it's not illegitimate to do a trial in this patient group necessarily. Okay.

But when I said they have a lot of suicidal acts 5 compared to major depressive disorder patients, for instance, 6 7 in 3,000-odd major depressive disorder patients, GSK reported 8 11 suicidal acts. In roughly 170 or maybe that's 150 patients 9 with intermittent brief depressive disorders, GSK report 34 10 suicidal acts. So you can see there's a vast difference here. 11 This is a group of patients who are regularly committing 12 suicidal acts. Almost every one of them nearly do. 13 Q. Well, how is using that data somehow able to hide a 14 suicide risk for regularly depressed patients? 15 Well, as the term "intermittent brief depressive disorder" Α. 16 suggests, you can view this condition as a mood disorder. You 17 can even view it as a kind of depression. Now, if you mix --18 I mean, one of the things that I could have told people, and 19 I've written articles on this, and it doesn't just apply for 20 depression. It applies for back pain and things like that.

If you mix patients with a back pain of different sources in together, then a treatment that might be helpful for one kind of back pain won't show up when you mix a bunch of different kinds of back pain together. Like, antibiotics can be good for some back pains, but if you just take all back

1	pain patients, it won't show.
2	In the same kind of way, you can hide a problem that
3	a drug causes by using a problem the drug causes. And that's
4	what's happening in this case. If you drown out you can
5	drown out the signal from 11 suicidal acts versus one by
6	adding in 34 to the 11 and 34 to the 1. All of a sudden, the
7	problem vanishes.
8	Q. Because the numbers are then 36 to 47; is that right?
9	A. Something like that, yes.
10	Q. Okay. This approach of trying to add in these data from
11	these studies, did GSK attempt to do that when they came to
12	the suicide issue?
13	A. Well, GSK certainly did the studies that would do that
14	would have that kind of effect. And their view was, people
15	looking at this issue should mix the two. They should mix
16	major depressive disorder with intermittent brief depressive
17	disorder if you want to get a true picture of what was going
18	on.
19	Q. And if you do mix them, what happens to the suicide
20	signal?
21	A. Well, if you mix them, the suicide signal goes away, and
22	this this is something that GSK have done ordinarily.
23	Q. Now, these studies, these 056 there's a buzzing noise.
24	These studies, did they 057 and 106, did they did the
25	FDA consider them in their FDA analysis?

	Healy - direct by Wisner 538
1	A. In the 2006 one, no, they didn't. GSK asked thought,
2	made representations to the FDA that they should be included
3	in. FDA said no.
4	Q. All right. Let's move on to the next way GSK hid the
5	data. What's the next one, Doctor?
6	A. The next one I've got here is discounting run-out
7	suicides.
8	Q. What's a run-out, Doctor?
9	A. Well, as opposed to the run-in, this is the wash-out
10	phase. Before you randomize, there's a run-out period. When
11	the trial ends after, say, six weeks, there's a 30-day period
12	where people should monitor the patients who have been in both
13	arms, the active treatment arm and the placebo arm. So this
14	is often called the run-out phase.
15	Q. And I understand, Doctor, in your expert report, you
16	prepared a diagram that helps you explain this?
17	A. I did, yes.
18	Q. Would using that diagram today help you in explaining how
19	that works?
20	A. Yes.
21	MR. WISNER: Your Honor, permission to publish
22	Exhibit Plaintiff's Exhibit 42 for demonstrative purposes
23	only.
24	BY MR. WISNER:
25	Q. All right. This is from your expert report, Doctor. What

	Healy – direct by Wisner 539
1	is this?
2	A. This is Figure 3. It may be helpful to show Figure 1 and
3	2 briefly so people can see what's going on.
4	Q. Sure. Let me pull it up.
5	A. Just the previous page.
6	MR. WISNER: Your Honor, can I show the previous
7	figure?
8	THE COURT: Yes.
9	BY MR. WISNER:
10	Q. Okay. All right. So walk us through this, Doctor. This
11	is from your report.
12	A. What you see here is what I have been trying to explain.
13	You can leave that as it is. Hold on so the jury can see.
14	You don't need to blow anything up.
15	You see the three dots up at the top, that's the
16	placebo that's the suicide attempts happening during the
17	wash-in wash-out or run-in phase. And you see in Figure 2
18	down below, they've migrated down to they appear to be in
19	the placebo arm, and that makes the
20	Q. I'm listening, Doctor. Sorry.
21	A. That makes the difference between Paxil and placebo look
22	less. Now, if we go on to the next slide.
23	Q. Okay. Just for the record, that was exhibit
24	Plaintiff's Exhibit 42.
25	A. Okay.

	Healy - direct by Wisner 540	
1	Q. Sorry.	
2	A. Okay.	
3	Q. Yes.	
4	A. And on the next	
5	Q. Sorry. That was Plaintiff's Exhibit 43. Now we're on	
6	Exhibit 42. Okay. Sorry, Doctor.	
7	A. Okay. On the next slide, there have been concerns about	
8	this. And you've seen the documents even within GSK. There	
9	were concerns that people weren't happy with the way this was	
10	being done. So this document reverses that	
11	MR. BAYMAN: Your Honor, that is just he is now	
12	just	
13	THE COURT: Yes, it may go out. Sustained.	
14	MR. BAYMAN: I move to strike.	
15	THE COURT: Yes. Your motion is granted.	
16	BY MR. WISNER:	
17	Q. All right, Doctor.	
18	A. Okay.	
19	Q. Please don't talk about concerns.	
20	A. Sorry.	
21	Q. Just talk about what the data is.	
22	A. Okay. In GSK, they thought it would be more appropriate	
23	not to include the wash-outs in the placebo arm, and this	
24	document reverses that. The wash-out suicides have gone back	
25	up to the wash-out phase. But what you see down below is, a	

further way to change things is to add suicides or suicide
 acts, and these are two completed suicides, into the placebo
 arm.

One -- the first little bullet you see there
happening shortly after the dotted line where it's migrating
up to the placebo arm is a person who is on placebo in the
trial, and then in the wash-out period, they end up in
hospital, being given Prozac, and they commit suicide on
Prozac but they're being regarded as a placebo suicide.

10 The bullet you see down below the closed line 11 completely is a person who falls -- whose death happens 12 outside the 30-day period. And again, that's being counted in 13 the placebo arm.

14 So to be clear, Doctor, these are patients who are in the Q. 15 placebo arm, left the study, and then had a suicide event, and 16 that was counted as though it happened in the study --17 A. No, they hadn't actually left the study. Monitoring 18 should happen, so they're still being observed, but it's 19 terribly difficult to regard a person who commits suicide 20 after going on Prozac as a placebo suicide. This just doesn't 21 make a great deal of sense.

Q. I understand. So this was a Paxil trial, but the placebo
patient was put on Prozac at the hospital --

24 A. After the trial was over --

25 Q. I see.

	Healy - direct by Wisner 542
1	A during that 30-day period.
2	Q. And okay.
3	A. The suicide happens during a period when the patient
4	should be monitored, but it only happens after they go on
5	Prozac.
6	Q. And so what does that essentially do to the placebo count?
7	A. Well, this gives you the impression that there was only
8	one suicide on Paxil, and you're given the impression actually
9	overall when this takes place that there were three suicides
10	on placebo when there weren't.
11	Q. Okay.
12	A. At least you can debate whether that should be counted
13	that way or not.
14	Q. What do you think it should be?
15	A. Well, I don't think it should be counted that way.
16	Q. Okay. All right. Doctor, what's the next way GSK hid the
17	data? What number are we up to, five?
18	A. We're getting through them all right. Coding maneuvers.
19	Q. What is coding maneuvers?
20	A. Well, these days, almost all people use a coding
21	dictionary called MedDRA. If I'm trying to code things, the
22	team I work with will be using the MedDRA coding dictionary.
23	And that's the one that FDA recognizes, also.
24	Before that, the main dictionary used by FDA was a
25	dictionary called COSTART, but when it came to these trials

during this period, GSK was using a dictionary called ADEX.
And using ADEX, they had an option to code suicides, completed
suicides, and suicidal acts and suicidal ideation under the
heading of "emotional lability."

And when that happened, people like me reading an 5 6 article where this term appears in 2001, as it turned out, 7 missed the fact that what's happening here is something 8 awfully serious. We just think emotional lability is no big 9 deal. We don't realize it's been used not -- it's -- I think 10 English has been used. In fact, what's been used is coding 11 language. And in coding language, it means a completely 12 different thing to what the average doctor or person who may 13 be on the pill thinks.

14 MR. BAYMAN: Objection, your Honor. He's speculating15 about what the average doctor thinks or knows.

16

THE COURT: Overruled at this point.

17 THE WITNESS: Okay. So there's a range of different 18 things, and I've got an article on this which goes through the 19 range of different coding maneuvers that GSK used in the Paxil 20 trials. It's not confined to just emotional lability, but 21 that was clearly the key one.

And just, this is -- let's put it this way. My view on it has been a doctor like me reading the article would be fooled. A layperson like the jury would be more likely to look at this article and say --

	Healy - direct by Wisner 544
1	MR. BAYMAN: Objection, your Honor.
2	THE COURT: Overruled.
3	THE WITNESS: It was, in fact, laypeople that spotted
4	the problem, not experts like me. So we have to be thankful
5	for laypeople like the jury. You don't want to depend just on
6	experts to get this right.
7	BY MR. WISNER:
8	Q. Are you aware of whether or not the FDA ever caught GSK
9	doing this?
10	A. Well
11	MR. BAYMAN: Objection, your Honor.
12	THE COURT: Yes, sustained as to whether they caught
13	them.
14	BY MR. WISNER:
15	Q. Fair enough. Are you aware of whether or not the FDA ever
16	expressed concern over GSK's coding maneuvers?
17	A. They did. They wrote to GSK and asked them to clarify
18	where this term came from and to break out the data by
19	suicides and suicide attempts rather than emotional lability.
20	Q. Have you seen any internal email correspondence from
21	within the FDA about this point?
22	A. I have.
23	Q. And did it relate specifically to Paxil?
24	A. It did.
25	Q. All right. Please turn your binder to Exhibit 27. Are

 series of what is this, Doctor? A. This is a series of emails between individuals in FDA. Q. Is this a document that you relied upon in coming to your opinions today? A. Yes, it is. Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. 		Healy - direct by Wisner 545
 Q. All right. This is Plaintiff's Exhibit 27. And this is a series of what is this, Doctor? A. This is a series of emails between individuals in FDA. Q. Is this a document that you relied upon in coming to your opinions today? A. Yes, it is. Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	1	you there?
 4 series of what is this, Doctor? 5 A. This is a series of emails between individuals in FDA. 6 Q. Is this a document that you relied upon in coming to your 7 opinions today? 8 A. Yes, it is. 9 Q. And is this to be a fair and truthful, accurate 10 representation of a document that you reviewed? 11 A. It appears to be. 12 Q. Okay. Great. And does it discuss this coding issue? 13 A. It does, yes. 14 MR. WISNER: Permission to publish, your Honor. 15 THE COURT: You may proceed. 16 BY MR. WISNER: 17 Q. All right. Let's start off let's start off at the top. 18 Let's look at this email exchange here. It's from who, 19 Doctor? 20 A. Which right. Okay. This is from Russell 21 MR. BAYMAN: Your Honor 22 THE WITNESS: Katz. 	2	A. Yes, I am.
 A. This is a series of emails between individuals in FDA. Q. Is this a document that you relied upon in coming to your opinions today? A. Yes, it is. Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	3	Q. All right. This is Plaintiff's Exhibit 27. And this is a
 Q. Is this a document that you relied upon in coming to your opinions today? A. Yes, it is. Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	4	series of what is this, Doctor?
 opinions today? A. Yes, it is. Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell THE WITNESS: Katz. 	5	A. This is a series of emails between individuals in FDA.
 A. Yes, it is. Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	6	Q. Is this a document that you relied upon in coming to your
 9 Q. And is this to be a fair and truthful, accurate representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	7	opinions today?
 representation of a document that you reviewed? A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	8	A. Yes, it is.
 A. It appears to be. Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	9	Q. And is this to be a fair and truthful, accurate
 Q. Okay. Great. And does it discuss this coding issue? A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	10	representation of a document that you reviewed?
 A. It does, yes. MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	11	A. It appears to be.
 MR. WISNER: Permission to publish, your Honor. THE COURT: You may proceed. BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	12	Q. Okay. Great. And does it discuss this coding issue?
 15 THE COURT: You may proceed. 16 BY MR. WISNER: 17 Q. All right. Let's start off let's start off at the top. 18 Let's look at this email exchange here. It's from who, 19 Doctor? 20 A. Which right. Okay. This is from Russell 21 MR. BAYMAN: Your Honor 22 THE WITNESS: Katz. 	13	A. It does, yes.
 BY MR. WISNER: Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	14	MR. WISNER: Permission to publish, your Honor.
 Q. All right. Let's start off let's start off at the top. Let's look at this email exchange here. It's from who, Doctor? A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	15	THE COURT: You may proceed.
 18 Let's look at this email exchange here. It's from who, 19 Doctor? 20 A. Which right. Okay. This is from Russell 21 MR. BAYMAN: Your Honor 22 THE WITNESS: Katz. 	16	BY MR. WISNER:
<pre>19 Doctor? 20 A. Which right. Okay. This is from Russell 21 MR. BAYMAN: Your Honor 22 THE WITNESS: Katz.</pre>	17	Q. All right. Let's start off let's start off at the top.
 A. Which right. Okay. This is from Russell MR. BAYMAN: Your Honor THE WITNESS: Katz. 	18	Let's look at this email exchange here. It's from who,
21 MR. BAYMAN: Your Honor 22 THE WITNESS: Katz.	19	Doctor?
22 THE WITNESS: Katz.	20	A. Which right. Okay. This is from Russell
	21	MR. BAYMAN: Your Honor
23 MR. BAYMAN: Pediatrics.	22	THE WITNESS: Katz.
	23	MR. BAYMAN: Pediatrics.
24 THE COURT: Does this relate to the issue of coding?	24	THE COURT: Does this relate to the issue of coding?
25 MR. WISNER: It does, your Honor.	25	MR. WISNER: It does, your Honor.

